GMED vs TAK
Globus Medical vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | GMED | TAK |
|---|
| AI Score |
71
|
67
|
| Price |
$85.12
|
$17.49
|
| P/E Ratio |
21.45×
|
48.87×
|
| ROE |
11.8%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
62.1%
|
| Debt / Equity |
0.02×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
75.9
|
61.6
|
| Beta |
0.954
|
0.088
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus TAK.
GMED leads by 4 points.
GMED scores 71/100 (Buy) versus TAK at 67/100 (Insufficient Data).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical